Strong Albumin Solutions in Patients With Septic Shock
Key facts
- Who runs it
- Manchester University NHS Foundation Trust
- Where
- United Kingdom2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2/3
- People taking part
- 47 people enrolled
- Started
- 10 Nov 2023
- Ended
- 31 Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- hyperoncotic human albumin solution
- Buffered crystalloid solutions
- Record updated
- 9 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Suspected or documented infection
- Organ dysfunction defined as SOFA score ≥2
- Need for vasopressor infusion for ≥2 hours
- Serum lactate ≥2 mmol/L
- Eligible for critical care admission without any restrictions
Who cannot take part
- Previous enrolment in this study
- Patients with a known allergy to albumin
- Previous receipt of human albumin solution for the episode of sepsis in question
- <18 years of age
- >24 hours since the time point of meeting all inclusion criteria
- Pregnancy
- Jehova's witnesses or other patients expressing a known objection to the use of blood products
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Sepsis is an increasingly recognised burden to healthcare systems worldwide. Intravenous fluid therapy is a common first-line intervention recommended by international guidelines. Hyperoncotic preparations of human albumin solution are widely available, but their efficacy has yet to be proven.
Read full original descriptionShow less
This randomised feasibility trial will test whether it is feasible to administer hyperoncotic albumin solutions as both fluid resuscitation and as a regular supplement in patients with early septic shock.
The 2 groups in the trial
- Hyperoncotic albuminTreatment being tested
Hyperoncotic albumin for all fluid resuscitation and also as a daily supplement, guided by daily serum albumin values, for up to 7 days.
Treatment: hyperoncotic human albumin solution
- Buffered crystalloidsExisting treatment, for comparison
Buffered crystalloid solutions for all fluid resuscitation and maintenance purposes. Participants in this arms will NOT receive any albumin during their participation.
Treatment: Buffered crystalloid solutions
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Small Volume Fluid Resuscitation and Supplementation With 20% albumIn Versus Buffered Crystalloids in PatiEnts With Septic Shock
- Record updated
- 9 February 2026